The Role of DLBS1033 in The Management of Acute Non-ST Elevation of Myocardial Infarction (NSTEMI) Without Early Coronary Revascularization

Trial Profile

The Role of DLBS1033 in The Management of Acute Non-ST Elevation of Myocardial Infarction (NSTEMI) Without Early Coronary Revascularization

Withdrawn prior to enrolment
Phase of Trial: Phase II/III

Latest Information Update: 22 Apr 2016

At a glance

  • Drugs Lumbricus rubellus (Primary) ; Aspirin; Clopidogrel
  • Indications Myocardial infarction
  • Focus Therapeutic Use
  • Sponsors Dexa Medica
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Apr 2016 Planned End Date changed from 1 Feb 2018 to 1 Mar 2018.
    • 18 Apr 2016 Status changed from recruiting to withdrawn prior to enrolment as the investigational cases were no longer relevant considering the recent implementation of our current national healthcare system.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top